Clinical Trial Search

Primary: Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS) — 12.0…

Primary: Number of Participants With TEAEs, SAEs, and Severe TEAEs - Part 1: SAD — 1; 1; 2; 2 Participants

Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19

Primary: Correlation Between Striatal D2 Receptor Binding Potential (D2BP) as Measured by [18F]Fallypride and [11C]Raclopride Time-activity Curves — 0.468 Correlation Coefficient

Primary: Alcohol Impaired Driving Behavior — 67; 60; 36; 29 Count of driving episodes after drinking

Primary: The Interpersonal Needs Questionnaire-15 (INQ-15) - Thwarted Belongingness — -0.29 Cohen's d effect size

Primary: Objective Response Rate (ORR) — 52.3 percentage of participants

Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) of Pain Intensity Scores From Time 0 (When First Dose on Day 1 is Administered) Through 24 Hours…

Primary: Trough CBD Plasma Levels — 0; 0.7 CBD (ng/mL)

Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24 — 0.8; 29.6; 41.5 percentage of participants — p=<0.0001

Primary: Contextual Factors Associated With Tobacco Use Episode Reported Via Ecological Momentary Assessment — 3; 22; 11; 12 tobacco use episodes — p=0.002

Primary: Number of Participants With at Least One Treatment-related Adverse Event — 10; 7 Participants

Primary: Change in Parathyroid Hormone Levels — 4.0; -3.7; 0.8 pg/mL — p=0.84

Primary: Change in Minimal Fibrous Cap Thickness (FCT) — 70.9; 97.7 µm

Primary: Change in Limb Volume — 8; 2 Participants